RPS6 and acute myeloid leukemia: Sirolimus combination with MEC was tolerable in patients with high risk AML; however, the combination therapy did not enhance clinical responses in AML and was limited to patients presenting baseline mTORC1 activation as measured by baseline rpS6 phosphorylation.